Tag Archives: Duchenne Muscular Dystrophy
A Better Balance Between Accelerated Access And High-Priced New Drugs: A New Conditional Approval Option
A new form of “conditional approval” could accelerate the approval of new drugs and, at the same time, take at least a small step towards reducing the costs of potentially life-saving drugs.
March 20, 2017
What can we learn from the Food and Drug Administration’s controversial approval of the first drug for Duchenne Muscular Dystrophy (DMD)?
October 25, 2016